drugset / Trial / NCT03762031
A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
The study will be a Phase 1, randomized, double-blind, placebo-controlled, single dose escalation study designed to evaluate the safety and PK of intravenously administered superoxide dismutase mimetic GC4711 in healthy volunteers.
Timeline
- Start
- 2019-03-19
- Primary completion
- 2020-03-04
- Completion
- 2020-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 30 mg | Intravenous |
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 60 mg | Intravenous |
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 75 mg | Intravenous |
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 90 mg | Intravenous |
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 105 mg | Intravenous |
| Subject | RUCOSOPASEM MANGANESE | Other / unclassified | 120 mg | Intravenous |
Indications
No indication recorded.